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Human adenovirus type 9 exclusively elicits mammary tumors in experimental animals, and the primary
oncogenic determinant of this virus is the E4-ORF1 oncogene, as opposed to the well-known E1A and E1B
oncogenes. The tumorigenic potential of E4-ORF1, as well as its ability to oncogenically stimulate phospha-
tidylinositol 3-kinase (PI3K), depends on a carboxyl-terminal PDZ domain-binding motif (PBM) that mediates
interactions with several different membrane-associated cellular PDZ proteins, including MUPP1, PATJ,
MAGI-1, ZO-2, and Dlg1. Nevertheless, because certain E4-ORF1 mutations that alter neither the sequence
nor the function of the PBM abolish E4-ORF1-induced PI3K activation and cellular transformation, we
reasoned that E4-ORF1 must possess an additional crucial protein element. In the present study, we identified
seven E4-ORF1 amino acid residues that define this new element, designated domain 2, and showed that it
mediates binding to a 70-kDa cellular phosphoprotein. We also discovered that domain 2 or the PBM
independently promotes E4-ORF1 localization to cytoplasmic membrane vesicles and that this activity of
domain 2 depends on E4-ORF1 trimerization. Consistent with the latter observation, molecular-modeling
analyses predicted that E4-ORF1 trimerization brings together six out of seven domain 2 residues at each of
the three subunit interfaces. These findings importantly demonstrate that PI3K activation and cellular
transformation induced by E4-ORF1 require two separate protein interaction elements, domain 2 and the
PBM, each of which targets E4-ORF1 to vesicle membranes in cells.
Studies of human adenovirus (Ad) have greatly contributed
to our understanding of mechanisms leading to the develop-
ment of human cancers (65). The 51 different serotypes of
human Ad are classified into six subgroups (A through F), and
while Ad infection is not linked to human cancers, all subgroup
A and B Ads and two subgroup D Ads can elicit tumors in
experimentally infected immune-competent rodents (50).
Nonetheless, the two subgroup D viruses, Ad type 9 (Ad9) and
Ad10, differ strikingly from subgroup A and B Ads by solely
eliciting estrogen-dependent mammary tumors, as opposed to
undifferentiated sarcomas, in animals (22). In accordance with
these two distinct tumorigenic phenotypes, the primary onco-
genic determinant of subgroup D Ad9 is the E4 region-
encoded open reading frame 1 (E4-ORF1) protein (23, 54)
rather than the E1 region-encoded E1A and E1B proteins of
subgroup A and B Ads (55). Moreover, replacement of the E1
region in nontumorigenic subgroup C Ad5 with an Ad9 E4-
ORF1 expression cassette confers a tumorigenic phenotype
virtually identical to that of Ad9 (54), indicating that E4-ORF1
likewise controls the oncogenic tropism of Ad9 for mammary
gland tissue.
Evidence suggests that Ad E4-ORF1 genes evolved from an
ancestral cellular dUTP pyrophosphatase (dUTPase) gene
(63), which encodes an essential enzyme of nucleotide metab-
olism. This enzyme functions to maintain low dUTP levels in
cells, thereby preventing detrimental uracil incorporation into
replicating DNA (40). Nevertheless, E4-ORF1 neither pos-
sesses this enzymatic activity nor binds or perturbs the function
of cellular dUTPase, indicating that these two related proteins
have functionally diverged. Results instead suggest that E4-
ORF1 exploited the structural framework of the homotrimeric
dUTPase enzyme to develop novel cellular growth-promoting
activities (63).
The tumorigenic potential of E4-ORF1 depends on a class 1
PDZ domain-binding motif (PBM) having the consensus se-
quence -(S/T)-X-(V/I/L)-COOH (where X is any amino acid
residue) located at its extreme carboxyl terminus (13). This
crucial protein interaction element mediates binding to a select
group of cellular PDZ proteins, including MUPP1, PATJ,
MAGI-1, ZO-2, and Dlg1 (14, 15, 26, 28, 29), most of which
are suspected tumor suppressors (7, 15, 33, 56). In general,
PDZ proteins function as multivalent scaffolds to organize
supramolecular signaling complexes and to localize them to
specialized regions of cell-cell contact at the plasma mem-
brane, such as the adherens junction or tight junction (TJ) of
epithelial cells (49). Further underscoring the relevance of
cellular PDZ proteins to human cancer, the Tax oncopro-
tein of human T-cell leukemia virus type 1 and the E6 onco-
proteins of high-risk human papillomaviruses likewise possess
a carboxyl-terminal class 1 PBM that mediates binding to sev-
eral different cellular PDZ proteins, including one or more of
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those targeted by E4-ORF1 (14, 26, 28, 29). Like the PBM of
E4-ORF1, the PBMs of Tax and E6 also contribute to their
capacities to transform cells (18, 39, 60).
TJ disruption and a loss of apicobasal polarity are common
defects of epithelium-derived cancer cells, and accumulating
evidence suggests that such deficiencies directly contribute to
carcinogenesis (34). It is therefore notable that the E4-ORF1-
interacting PDZ proteins MUPP1, PATJ, MAGI-1, and ZO-2
associate with the TJs of epithelial cells (16, 21, 24, 30) and that
both PATJ, an evolutionarily conserved polarity protein (30),
and ZO-2 represent key regulators of TJ biogenesis (51, 57).
Moreover, in epithelial cells, E4-ORF1 via its PBM prevents
proper TJ localization of PATJ and ZO-2 by directly seques-
tering them in the cytoplasm and, in doing so, disrupts the TJ
barrier function and causes a loss of apicobasal polarity (26).
This finding supports the idea that E4-ORF1 inactivates the TJ
functions of both PATJ and ZO-2 in epithelial cells. The fact
that E4-ORF1 similarly sequesters MUPP1, MAGI-1, and
ZO-2 in the cytoplasm of fibroblasts (14, 15, 28), which lack
TJs, suggests that inactivation of TJ-independent functions of
these cellular PDZ proteins, such as the tumor suppressor
activity of ZO-2 (15), also contributes to the oncogenic poten-
tial of E4-ORF1.
An additional crucial PBM-dependent activity of E4-ORF1
is oncogenic stimulation of cellular phosphatidylinositol 3-ki-
nase (PI3K) (13). PI3K represents a key component of a sig-
naling pathway that regulates cellular metabolism, survival,
growth, and proliferation (4, 25) and that is also commonly
activated in a wide spectrum of human cancers (36, 46, 47).
Recent findings demonstrated a specific requirement for the
adherens junction-associated PDZ protein Dlg1 in Ras-depen-
dent E4-ORF1-induced PI3K activation, exposing a previously
unrecognized oncogenic function for this cellular tumor sup-
pressor protein (12). In addition, PBM-mediated binding of
E4-ORF1 triggers Dlg1 translocation to sites of PI3K activa-
tion at the plasma membrane (12, 13), contrasting with the
cytoplasmic sequestration of TJ-associated PDZ proteins.
Despite the central importance of the PBM for E4-ORF1
activity, certain E4-ORF1 mutations that alter neither the
PBM sequence nor its binding function, including cytoplasmic
sequestration of TJ-associated PDZ proteins (26) and plasma
membrane translocation of Dlg1 (12), abrogate E4-ORF1-in-
duced PI3K activation and cellular transformation, as well as
mammary tumorigenesis in the context of Ad9 (13, 61). These
observations indicate that the latter activities of E4-ORF1 de-
pend not only on its PBM, but also on an additional poorly
characterized protein element. In this paper, we define this
second crucial element, designated domain 2, and show that it
functions to mediate both binding to a 70-kDa cellular phos-
phoprotein and association with membrane vesicles in cells.
MATERIALS AND METHODS
Protein sequences and alignments. Human Ad9 (P89079), Ad12 (AP 000141),
Ad3 (ABB17792), and Ad5 (AP 000232) E4-ORF1 protein sequences were
acquired from The National Center for Biotechnology Information protein da-
tabase. The AlignX application module of the Vector NTI 7 software package
(InforMax Inc.) was used to generate multiple-sequence alignments.
Mutagenesis and plasmids. Ad9 E4-ORF1 mutations were generated by the
recombinant PCR method (19). E4-ORF1 mutant genes were inserted into plas-
mid pJ4 (66), pGEX-2TK (Pharmacia), or pBABE-puro (38) at the BamHI and
EcoRI sites and verified by sequencing. The cDNAs coding for six-histidine-
tagged human dUTPase (His-dUTPase) and some E4-ORF1 mutants were in-
serted into plasmid GW1 (British Biotechnology) at the HindIII and EcoRI sites.
Plasmids pJ4, GW1, and pGEX-2TK coding for wild-type (wt) E4-ORF1 or
mutant E4-ORF1 IA, L89Q, F91S, IIIA, A122D, T123D, L124P, or V125A were
described previously (13, 61, 62). Plasmid pME-VSVG, coding for vesicular
stomatitis virus G glycoprotein, was a gift of K. Maruyama.
Cells, transfections, and extract preparation. CREF (11), NIH 3T3 (ATCC),
TE85 (35), and 293T (42) cell lines were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 6% to 10% fetal bovine serum
(FBS) and 20 g/ml gentamicin. Transfections were conducted with either Fu-
gene6 (Roche Molecular Biochemicals), TransIT LT1 (Mirus Bio Corporation),
or Lipofectamine (Invitrogen Corporation) as recommended by the manufac-
turers. Cell extracts in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate
[SDS]) supplemented with protease inhibitors and phosphatase inhibitors were
prepared as described previously (29). Prior to extract preparation, some cells
were either serum starved by incubation in FBS-free DMEM for 16 h or meta-
bolically radiolabeled on a 10-cm dish by incubation with 0.5 mCi of
[32P]orthophosphate in phosphate-free DMEM containing 6% dialyzed FBS for
4 h at 37°C. The protein concentrations of cell extracts were determined by the
Bradford method (2).
For fractionation assays, cells were lysed in RIPA buffer and then centrifuged
(10,000  g for 5 min at 4°C) to isolate detergent-soluble supernatant and
detergent-insoluble pellet fractions. The pellet fraction was subsequently solu-
bilized in a volume of sample buffer (65 mM Tris-HCl, pH 6.8, 1% SDS, 5%
-mercaptoethanol, 10% glycerol, 0.005% bromophenol blue) equal to that of
the detergent-soluble supernatant fraction (26). Experiments compared equal
volumes of the detergent-soluble supernatant and detergent-insoluble pellet
fractions.
Cell line production. Cell lines were generated by either transfection of plas-
mids using Fugene6 or transduction with retroviral vectors (13, 52). Vesicular
stomatitis virus G-pseudotyped murine leukemia retrovirus vectors were pro-
duced by cotransfection of 293T cells with plasmids pHIT60, pME-VSVG, and
pBABE-puro carrying either wt or mutant E4-ORF1 genes, as described previ-
ously (52). Cells transfected or transduced with pBABE-puro plasmids were
selected and maintained in culture medium supplemented with 10 g/ml puro-
mycin. Experiments utilized pooled puromycin-resistant cells.
Antibodies. Rabbit polyclonal antiserum to Ad9 E4-ORF1 or ZO-2 were
described previously (15, 23). Antibodies to protein kinase B (PKB) and
phospho-PKB (Thr308) (Cell Signaling Technologies), Dlg1 (BD Transduc-
tion Laboratories), and clathrin heavy chain (Sigma) were purchased, as were
rhodamine-conjugated donkey anti-goat immunoglobulin G (IgG) and Alexa
Fluor 488-conjugated goat anti-rabbit IgG (Molecular Probes) and horserad-
ish peroxidase-conjugated goat anti-rabbit and anti-mouse IgG (Southern
Biotechnology Associates Inc.).
Immunoblot, GST pull-down, and immunoprecipitation assays. Immunoblot
analyses were conducted as described previously (13). Glutathione S-transferase
(GST) pull-down or immunoprecipitation assays were performed as described
previously (62), except that cell extracts in RIPA buffer were preincubated with
either glutathione-Sepharose beads (Amersham Biosciences) bound to GST or
protein A-Sepharose beads (Amersham Biosciences) for 3 h. In some experi-
ments, the recovered proteins were incubated in digestion buffer (10 mM Tris-
HCl, pH 8.0, 0.1% SDS, 5 mM EDTA) containing 10 g/ml proteinase K (Roche
Molecular Biochemicals) prior to subsequent analyses.
Focus formation and IF assays. Focus formation and immunofluorescence
(IF) assays were carried out as described previously (13, 23). For IF assays, cells
cultured on coverslips were fixed for 30 min at room temperature in freshly
prepared 4% paraformaldehyde (Polysciences, Inc.) and permeabilized for 5 min
at room temperature in 0.5% Triton X-100. The coverslips were mounted on
slides with Slowfade Light (Molecular Probes), and cells were visualized with a
Zeiss Axioplan 2 epifluorescence microscope and photographed with a CoolSnap
HQ charge-coupled device camera (Photometrics).
Size exclusion chromatography. Extracts from E4-ORF1-expressing cells in
RIPA buffer (200 l) were mixed with size markers (200-kDa -amylase, 66-kDa
bovine serum albumin, 43-kDa ovalbumin, 29-kDa carbonic anhydrase, and
12.4-kDa cytochrome c [Sigma-Aldrich Co.] and 48.6-kDa recombinant trimeric
His-dUTPase expressed in 293T cells) prior to being loaded on a Superose 6
10/300 size exclusion column (Amersham Biosciences) preequilibrated with TBS
elution buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10% glycerol, 0.1%
sodium deoxycholate). A Pharmacia LKB Biotechnology fast protein liquid chro-
matography system was employed to run samples through the column with
elution buffer at a flow rate of 0.2 ml/min and to collect 300-l fractions. Aliquots
of each fraction were separated by SDS-polyacrylamide gel electrophoresis
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(PAGE) and immunoblotted with E4-ORF1 antibody. Size markers were visu-
alized by staining them with Coomassie brilliant blue, except for His-dUTPase,
which was detected by immunoblotting it with the His probe antibody (Santa
Cruz).
Molecular modeling. 3D-JIGSAW automatic modeling server software (1) and
MacPyMol software (DeLano Scientific LLC) were used to model the E4-ORF1
protein to the crystal structure of trimeric human dUTPase (Protein Data Bank
accession number 1Q5H) and to generate surface representations of the E4-
ORF1 trimer, respectively.
RESULTS
Mutational analysis of conserved residues in Ad9 E4-ORF1.
The existence of an additional crucial protein element, re-
ferred to as domain 2, in Ad9 E4-ORF1 is suggested by the
unique characteristics of E4-ORF1 triple point mutant IA
(F34I/H39Q/V41A) and single point mutants IIA (L89Q) and
IIB (F91S) (61). Specifically, these three domain 2 mutants
carry mutations situated outside of the PBM sequence (Fig. 1)
and accordingly retain wt binding to cellular PDZ proteins (26,
62) yet fail to promote either PI3K activation or cellular trans-
formation (13, 61). To further define domain 2, we sought to
isolate additional E4-ORF1 mutants with the same character-
istics. As we noted that the domain 2 mutation F91S alters one
of 33 conserved amino acid residues among subgroup A
through D human Ad E4-ORF1 proteins, all of which stimu-
late PI3K and transform cells (13, 61, 63), and that all con-
served residues except alanine 122 lie outside of the PBM
sequence (Fig. 1), our chosen approach for isolation of addi-
tional domain 2 mutants was to introduce a point mutation into
each conserved residue of the 125-residue Ad9 E4-ORF1
polypeptide.
A previous study had already reported the characterization
of Ad9 E4-ORF1 mutants with point mutations in 8 of the 33
conserved residues (61). One of these mutants (N92I) was not
stably expressed, and among the remaining seven expression-
competent mutants, five (Q19L/Q19G, F34I, L46P, L90V, and
V106A) displayed approximately wt cellular transforming ac-
tivity whereas two (domain 2 mutant F91S and PBM mutant
A122D) retained no or very limited cellular transforming ac-
tivity (Fig. 1) (61). In the present study, we therefore con-
structed a panel of new Ad9 E4-ORF1 mutants in which each
of the remaining 25 conserved residues was changed to an
alanine residue, except for conserved glycine residues, which
were changed to either a threonine or a valine residue.
Isolation of five new candidate domain 2 mutants. Two basic
characteristics of the original domain 2 mutants, as well as
PBM mutants, are wt protein expression and severe cellular
transformation defects, so we used these two criteria in our
initial screening of the 25 new Ad9 E4-ORF1 mutants. In
transient-expression assays with CREF fibroblasts, 11 mutants
exhibited either severe (P17A, Y26A, L109A, and P117A) or
moderate (E3A, L5A, G13T, P31A, G58T, E85A, and L86A)
protein expression defects compared to wt E4-ORF1 (Fig. 2A)
and therefore were not further investigated. The other 14 mu-
tants displayed wt protein expression, although 9 of them man-
ifested either approximately wt (V88A and D95A with 85%
of wt focus formation) or appreciable (Y6A, P38A, L44A,
P53A, G55T, L63A, and V119A with 19% to 44% of wt focus
formation) cellular transforming activity (Fig. 2A to C) and
therefore also were not further investigated. By contrast, the
remaining five mutants exhibiting wt protein expression satis-
fied our initial criteria for candidate domain 2 mutants by
showing either minimal (F97A and R113A with 1% or 7% of
wt focus formation, respectively) or no detectable (G40V,
D65A, and H93A) cellular transforming activity (Fig. 2A to C);
the latter phenotype matches that of the original domain 2
mutants IA, L89Q, and F91S and PBM mutants IIIA, T123D,
and V125A (Fig. 1) (13). Because we subsequently discovered
a PBM defect for mutant R113A (S. H. Chung, unpublished
data), however, only mutants G40V, D65A, H93A, and F97A
were selected for further characterization.
We next wanted to identify which of the three point muta-
tions (F34I/H39Q/V41A) in domain 2 mutant IA (Fig. 1) is
primarily responsible for its severe cellular transformation de-
fects; however, the previously reported transformation-profi-
cient phenotype of an Ad9 E4-ORF1 mutant carrying the F34I
mutation (61) focused this effort on the H39Q and V41A
FIG. 1. Mutations in domain 2, TRI, and PBM elements of the Ad9 E4-ORF1 protein. A multiple-sequence alignment of Ad subgroup A to
D E4-ORF1 protein sequences reveals 33 conserved amino acid residues (boldface). The filled circles are placed above 25 such Ad9 E4-ORF1
residues mutated in the current study. Also depicted are the locations of residues defining domain 2, TRI (VKI, residues 119 to 121), and core
PBM (ATLV, residues 122 to 125) elements of the Ad9 E4-ORF1 polypeptide. The names of all Ad9 E4-ORF1 mutants are also shown, with
boldface names indicating the seven mutants that define domain 2. For PBM and TRI/PBM mutants, underlined residues or dashes represent
substituted or deleted residues, respectively.
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mutations. Indeed, the results from focus formation assays
demonstrated that, whereas mutant H39Q retains substantial
cellular transforming activity, albeit somewhat less than wt
E4-ORF1, mutant V41A behaves identically to mutant IA in
lacking any detectable cellular transforming activity despite
expressing wt levels of protein (Fig. 2D and E).
In summary, our results designated G40V, V41A, D65A,
H93A, and F97A candidate domain 2 mutants. The experi-
FIG. 2. Protein expression and cellular transformation phenotypes of 25 new Ad9 E4-ORF1 mutants. (A) Transient expression levels of
E4-ORF1 mutant proteins. CREF fibroblasts on 6-cm dishes were transfected with 3.5 g of empty pJ4 plasmid (vector) or pJ4 plasmid coding
for either wt E4-ORF1 (wt) or the indicated mutant E4-ORF1. An equivalent amount of each cell extract (100 g protein) was immunoblotted
with E4-ORF1 antibodies. Two separate controlled experiments are presented in the top and bottom rows, with double vertical lines denoting the
locations of deleted irrelevant lanes. Similar results were obtained in four independent experiments. (B) Cellular transforming activities of
E4-ORF1 mutants. CREF fibroblasts were transfected with empty pJ4 plasmid (vector) or pJ4 plasmid coding for either wt E4-ORF1 (wt) or
the indicated mutant E4-ORF1, as for panel A. Transformed foci were counted at 3 weeks posttransfection. Focus-forming activity is reported as
the percentage of foci generated by each E4-ORF1 mutant relative to wt E4-ORF1, which was set at 100%. Data compiled from three independent
experiments include the means plus standard deviations. The names of mutants with or without protein expression defects, as determined by data
presented in panel A, are colored gray or black, respectively. The arrows point to candidate domain 2 mutants. (C) Photographs of selected focus
formation assays quantified in panel B. Only expression-competent Ad9 E4-ORF1 mutants are shown. (D) V41A is the crucial mutation in mutant
IA. Focus formation assays in CREF fibroblasts were carried out, quantified, and presented as described for panel B. Data compiled from two
independent experiments show the mean plus the range. The immunoblot assay comparing E4-ORF1 protein levels (top) was conducted as
described for panel A. (E) Photographs of focus formation assays quantified in panel D.
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ments detailed below investigated whether these five mutants
share additional properties with the original domain 2 mutants.
Candidate domain 2 mutants fail to stimulate the PI3K
pathway. Besides lacking cellular transforming activity, an-
other common defect of original domain 2 and PBM mutants
is the inability to stimulate the PI3K pathway in cells (13). We
therefore analyzed the five candidate domain 2 mutants for
their capacities to elevate cellular levels of activated, phospho-
rylated PKB, a key downstream effector of PI3K (4). Following
transient expression in 3T3 fibroblasts (Chung, unpublished)
or stable expression in CREF fibroblasts, wt E4-ORF1 sub-
stantially increased PKB phosphorylation on both serine resi-
due 473 (Chung, unpublished) and threonine residue 308,
whereas all candidate domain 2 mutants lacked this activity,
identically to the negative control empty plasmid (vector) (Fig.
3). These results are specific, because the transformation-pro-
ficient mutant V88A, which has a mutation adjacent to those of
the original domain 2 mutants L89Q and F91S (Fig. 2B and C),
behaved identically to wt E4-ORF1 in these assays.
Candidate domain 2 mutants bind to cellular PDZ proteins.
The one known characteristic that distinguishes the original
domain 2 mutants from PBM mutants is retention of binding to
cellular PDZ proteins. Consequently, we screened candidate
domain 2 mutants for this activity by subjecting them to GST
pull-down assays with extracts of CREF fibroblasts metaboli-
cally labeled with [32P]orthophosphate. Consistent with previ-
ous results (14, 15, 28, 29, 62), these assays revealed that
positive control wt E4-ORF1, mutant V88A, and original do-
main 2 mutants L89Q and F91S, but not negative control PBM
mutant IIIA, bind endogenously expressed, phosphorylated
forms of the E4-ORF1-associated cellular PDZ proteins (Fig.
4A and B). Importantly, like the original domain 2 mutants, all
five candidate domain 2 mutants retained this activity (Fig. 4A
and Fig. 5B and C).
This finding provided us with seven different domain 2 mu-
tants, two original mutants (L89Q and F91S) and five new
mutants (G40V, V41A, D65A, H93A, and F97A), which in
subsequent experiments were employed to expose functions
for domain 2.
Domain 2 defines a new protein interaction element. The
domains of DNA tumor virus oncoproteins generally act to
mediate interactions with critical cellular regulatory proteins
(17), so we hypothesized that domain 2 would perform the
same function for E4-ORF1. Indeed, the results of GST pull-
down assays presented in Fig. 4A and B additionally revealed
that wt E4-ORF1, PBM mutant IIIA, and transformation-pro-
ficient mutant V88A, but none of the seven domain 2 mutants,
interact with a 70-kDa cellular phosphoprotein (pp70). Similar
results were obtained with extracts from a 32P-labeled Ad9-
induced mammary tumor cell line (Chung, unpublished). We
also substantiated the designation of pp70 as a phosphoprotein
by showing its elimination by treatment with proteinase K (Fig.
4B) but not RNase A or DNase I (Chung, unpublished).
Significantly, a cellular protein comigrating with pp70 recov-
ered in GST pull-down assays coimmunoprecipitated with wt
E4-ORF1, but not domain 2 mutant F91S stably expressed in
human TE85 cells (Fig. 4C). The pp70 binding defect of mu-
tant F91S was specific, because cellular PDZ proteins effi-
ciently coimmunoprecipitated with this mutant. These findings
suggest that E4-ORF1 and pp70 form a complex in cells.
Four important conclusions were drawn from the experi-
ments described thus far. First, the common failure of domain
2 mutants to bind pp70 indicates that the seven domain 2
residues collectively define a single protein-interaction ele-
ment. Second, the reciprocal phenotypes of PBM mutant IIIA
versus domain 2 mutants in binding only to either cellular pp70
or cellular PDZ proteins, respectively, demonstrate that do-
main 2 and the PBM are independent protein interaction ele-
ments. Third, both domain 2 and the PBM are required for
PI3K activation and cellular transformation induced by E4-
ORF1. Fourth, the transformation-deficient phenotype of do-
main 2 mutants, which cannot bind pp70, coupled with the
transformation-proficient phenotype of the control mutant
V88A, which can bind pp70 (Fig. 4A), links the pp70 interac-
tion to cellular transformation.
Also noteworthy is the fact that, in the GST pull-down
assays presented in Fig. 4B, comparison of the protein bind-
ing profiles for PBM mutant IIIA and domain 2-PBM dou-
ble mutant F91S/IIIA exposed two additional putative do-
main 2-interacting cellular phosphoproteins migrating at
approximately 150 kDa and 190 kDa. While results with
domain 2 mutant F91S gave the impression that it unexpect-
edly binds to the 190-kDa protein, this band actually repre-
sents the E4-ORF1-associated PDZ protein MAGI-1, which
comigrates with the 190-kDa protein. These observations
hint that domain 2 mediates binding not only to pp70, but
also possibly to other cellular factors.
Domain 2 mutants form functional homotrimers and mono-
mers in cells. Unpublished results show that the 14-kDa Ad9
E4-ORF1 protein exists as both a trimer and a monomer in cells
(S. H. Chung, B. V. V. Prasad, and R. T. Javier, unpublished
data). We first measured the capacities of domain 2 mutants to
trimerize by subjecting extracts of 293T cells transiently express-
ing each protein to size exclusion chromatography in the presence
of 0.1% deoxycholate (DOC), a detergent that promotes quanti-
tative trimerization of oligomerization-competent E4-ORF1 pro-
teins. We found that all domain 2 mutants, as well as all PBM
mutants and the domain 2-PBM double mutant F91S/IIIA, eluted
similarly to wt E4-ORF1 at approximately 39 kDa (Fig. 5A),
consistent with the mass of a 42-kDa trimer. It is important to
note that the monomeric form of E4-ORF1 in cells was not
detected in these assays due to the presence of 0.1% DOC. The
trimerization competencies of the mutants described above are
concordant with the fact that mutations in neither domain 2 nor
the PBM affect the E4-ORF1 trimerization (TRI) element (Fig.
1). By contrast, even in the presence of 0.1% DOC, the control
FIG. 3. All five candidate domain 2 mutants fail to activate PKB.
PKB activation by stably expressed candidate domain 2 mutants. An
equivalent amount of extract (60 g protein) from serum-starved
CREF fibroblasts stably transfected with empty pBABE plasmid (vec-
tor) or pBABE plasmid coding for either wt E4-ORF1 (wt) or the
indicated mutant E4-ORF1 were immunoblotted with antibodies to
phospho-PKB (T308), PKB, or E4-ORF1.
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E4-ORF1 mutant C7, with a seven-residue carboxyl-terminal
deletion that eliminates both the TRI and PBM elements (Fig. 1),
instead eluted at approximately 13 kDa, comparable to the mass
of a 14-kDa monomer. The proper trimerization and PDZ pro-
tein binding observed for domain 2 mutants importantly argue
that their mutations do not cause gross protein misfolding.
The unpublished results mentioned above further indicate that
E4-ORF1 trimers and monomers perform distinct functions in
cells, where trimers bind to Dlg1 but monomers instead bind to
MUPP1, PATJ, MAGI-1, and ZO-2 and sequester them within
detergent-insoluble complexes. Thus, the facts that, in CREF
fibroblasts, stably expressed wt E4-ORF1 and all domain 2 mu-
tants, but not PBM mutant IIIA, efficiently coimmunoprecipi-
tated endogenous Dlg1 (Fig. 5B) and sequestered endogenous
ZO-2 within detergent-insoluble complexes (Fig. 5C) imply that
domain 2 mutants produce trimers and monomers that properly
bind to PDZ proteins. In addition, these findings extend the
results presented in Fig. 4A and B by showing that domain 2
mutants likewise retain a wt capacity to complex with PDZ pro-
teins in cells.
FIG. 4. Domain 2 is a new protein interaction element in Ad9 E4-ORF1. (A) Domain 2 mutants bind to cellular PDZ proteins but not
to cellular pp70 in GST pull-down assays. GST pull-down assays conducted with extracts (750 g protein) of [32P]orthophosphate-labeled
CREF fibroblasts were performed as described in Materials and Methods. The recovered proteins were resolved by SDS-PAGE and
visualized by autoradiography. An asterisk marks the location of the cellular pp70 band. The control Coomassie-stained gel (bottom) verified
the use of equivalent amounts of each GST-E4-ORF1 fusion protein. (B) Cellular pp70 is a phosphoprotein that binds to PBM mutant IIIA
but not domain 2 mutant F91S. GST pull-down assays were conducted as described for panel A. Recovered proteins were either mock treated
() or treated with proteinase K () for 30 min at 37°C and then analyzed as described for panel A. The control Coomassie-stained gel
(bottom) verified the use of an equivalent amount of each GST-E4-ORF1 fusion protein. Putative domain 2-interacting 150-kDa and
190-kDa proteins are marked with arrowheads. (C) Cellular pp70 coimmunoprecipitates with E4-ORF1. Human TE85 cells or the same cells
stably transduced with empty pBABE plasmid (vector) or pBABE plasmid encoding either wt E4-ORF1 (wt) or mutant F91S were
metabolically labeled with [32P]orthophosphate. Extracts (800 g protein) of TE85 cells were subjected to GST pull-down assays with the
indicated fusion proteins, whereas extracts (3 mg protein) of the indicated stably transduced TE85 lines were immunoprecipitated with
E4-ORF1 antibodies. Proteins recovered by pull-down (left) and immunoprecipitation (IP) (right) were resolved on the same SDS-PAGE
gel, and portions of the gel containing either cellular PDZ proteins (top) or pp70 (middle) were visualized by autoradiography. The data are
assembled into four separate properly aligned boxes to permit the presentation of optimal exposures. Other portions of the gel were either
Coomassie stained to verify the use of equivalent amounts of each GST fusion protein (lower left) or immunoblotted (IB) with E4-ORF1
antibodies to verify comparable immunoprecipitations of E4-ORF1 protein (lower right).
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Domain 2 or the PBM independently targets E4-ORF1 to
membrane vesicles. Though some E4-ORF1 localizes to the
plasma membrane (13), the majority of the protein associates
with numerous small punctae distributed throughout the cyto-
plasm (13, 64), a staining pattern strikingly similar to that of
membrane vesicles. Significantly, the results of IF assays re-
vealed that a substantial fraction of wt-E4-ORF1-containing
cytoplasmic punctae colocalized with clathrin-coated mem-
brane vesicles in CREF fibroblasts (Fig. 6A). This finding sug-
gests that the cytoplasmic punctae produced by E4-ORF1 re-
flect its association with clathrin-coated vesicles and likely
other types of membrane vesicles in cells. It is also important
to note that all data presented in Fig. 6A to C are represen-
tative of approximately 100% of the cells visualized in the IF
assays.
Previous results indicate, however, that disruption of either
the PBM alone or domain 2 alone does not abolish E4-ORF1
targeting to membrane vesicles (61). In this regard, PBM mu-
tants and original domain 2 mutants, as well as new domain 2
mutants (Chung, unpublished), retain the capacity to localize
to cytoplasmic punctae in CREF fibroblasts. We therefore
investigated whether disruption of both protein elements in
E4-ORF1 would abolish this localization. In CREF fibroblasts,
stably expressed domain 2 mutant F91S or PBM mutant IIIA
FIG. 5. Domain 2 mutants form functional homotrimers and monomers. (A) Domain 2 mutants properly trimerize. 293T cells on 6-cm dishes
were transfected with 3 g of GW1 plasmid coding for either wt E4-ORF1 (wt) or the indicated mutant E4-ORF1 using TransIT LT1, and cell
extracts were subjected to analytical size exclusion chromatography in the presence of 0.1% deoxycholate as described in Materials and Methods.
One-tenth of each eluted fraction was immunoblotted with E4-ORF1 antibodies. Only fractions containing E4-ORF1 are shown. The peak elution
fraction of each size marker is also indicated. (B) Endogenous Dlg1 coimmunoprecipitates with domain 2 mutants stably expressed in cells. Extracts
(250 g protein) from CREF fibroblasts transduced by empty pBABE retrovirus (vector) or pBABE retrovirus coding for either wt E4-ORF1 (wt)
or the indicated mutant E4-ORF1 were immunoprecipitated with E4-ORF1 antibodies. Recovered proteins or total cell extracts (60 g protein)
were immunoblotted with antibodies to E4-ORF1 or Dlg1. (C) Domain 2 mutants aberrantly sequester ZO-2 within detergent-insoluble complexes.
The CREF fibroblast lines shown in panel B were fractionated into detergent-soluble supernatant (S) and detergent-insoluble pellet (I) fractions
as described in Materials and Methods. The soluble fraction (60 g protein) and an equivalent amount of the insoluble fraction were subjected
to SDS-PAGE and immunoblotted with antibodies to E4-ORF1 or ZO-2.
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exhibited the expected punctate cytoplasmic staining patterns,
similar to that of wt E4-ORF1 (Fig. 6B), although mutant IIIA
produced somewhat more diffuse staining throughout the cell,
as reported previously (61). More importantly, the stably ex-
pressed double mutant F91S/IIIA, as well as G40V/IIIA and
D65A/IIIA (Chung, unpublished), failed to produce cytoplas-
mic punctae and instead exclusively localized diffusely in
CREF fibroblasts (Fig. 6B). The prominent diffuse nuclear
staining displayed by double mutants presumably reflects pas-
sive diffusion into the nucleus, given that control green fluo-
rescent protein localized similarly in these cells (K. K. Frese,
unpublished data). These findings indicate that domain 2 or
the PBM independently functions to target E4-ORF1 to mem-
brane vesicles.
The fact that E4-ORF1 trimers and monomers interact with
distinct subsets of the cellular PDZ protein targets prompted
additional experiments to determine whether one of these
forms likewise selectively mediates domain 2-dependent vesi-
cle association. With respect to this idea, we found that,
whereas the trimerization-competent PBM mutant C5 (Fig. 1
and 5A) displayed an expected punctate cytoplasmic staining
pattern in CREF fibroblasts, reflecting domain 2-dependent
targeting to membrane vesicles, the trimerization-incompetent
TRI-PBM double mutant C7 (Fig. 1 and 5A) instead exclu-
sively localized diffusely throughout the cells (Fig. 6C). We
were unable to establish whether this vesicle localization defect
of mutant C7 stems from a failure to bind pp70, because GST
dimerization complemented the trimerization deficiency of
TRI mutants in GST pull-down assays and because reduced
stable expression of TRI mutants relative to wt E4-ORF1 in
cells precluded interpretable comparisons in coimmunopre-
cipitation assays (Chung, unpublished). Nevertheless, our re-
sults show that trimers, but not monomers, of E4-ORF1 pro-
mote its domain 2-dependent association with membrane
vesicles in cells.
Predicted clustering of domain 2 residues at subunit inter-
faces of the E4-ORF1 trimer. Recent evidence suggests that
E4-ORF1 adopts a protein fold similar to that of human dUT-
Pase (S. H. Chung, B. V. V. Prasad, and R. T. Javier, unpub-
lished data), which functions as a homotrimer in cells (63).
Crystal structure data demonstrate that trimeric dUTPase con-
tains three identical catalytic sites, each consisting of a catalytic
cleft formed at the interface between two adjacent subunits
capped by a carboxyl-terminal nucleotide-binding P-loop motif
supplied by the third subunit (37). As our results show that
E4-ORF1 trimers, but not monomers, mediate domain 2-de-
pendent vesicle association (Fig. 6C), we modeled E4-ORF1
on the crystal structure of trimeric human dUTPase to pre-
dict the locations of domain 2 residues. Interestingly, this
analysis predicted that, in an E4-ORF1 trimer, six out of seven
domain 2 residues become clustered at each of the three sub-
unit interfaces, where adjacent subunits supply either residues
G40, V41, L89, and F91 or residues D65 and H93 (Fig. 7),
analogous to residues that form the dUTPase catalytic cleft
FIG. 6. Domain 2 or the PBM independently targets Ad9 E4-ORF1 to membrane vesicles. (A) E4-ORF1 colocalizes with clathrin-coated
vesicles in cells. CREF fibroblasts stably transfected with pBABE plasmid coding for wt E4-ORF1 were stained with E4-ORF1 (green) and clathrin
(red) antibodies and then visualized by epifluorescence microscopy, as described in Materials and Methods. The arrow points to a representative
vesicle where E4-ORF1 and clathrin colocalize. The area of interest is magnified in the inset. In the merged image, DAPI-stained nuclei are blue.
E4-ORF1 membrane staining is not evident under these experimental conditions. (B) Domain 2 mutant F91S and the PBM mutant IIIA, but not
domain 2-PBM double mutant F91S/IIIA, retain vesicular staining patterns. CREF fibroblasts stably transfected with pBABE plasmid coding for
either wt E4-ORF1 or the indicated mutant E4-ORF1 were stained with E4-ORF1 antibody and visualized by epifluorescence microscopy.
DAPI-stained nuclei are pseudocolored red. (C) E4-ORF1 trimers, but not monomers, possess domain 2 activity. CREF fibroblasts transduced
with empty pBABE plasmid (vector) or pBABE plasmid coding for the indicated E4-ORF1 mutant were stained with E4-ORF1 antibody and
visualized by epifluorescence microscopy. DAPI-stained nuclei are pseudocolored red.
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(37). This analysis also predicted that the E4-ORF1 carboxyl-
terminal PBM occupies a separate location analogous to the
more extended dUTPase carboxyl-terminal arm containing the
P-loop motif (Fig. 7).
DISCUSSION
Previous findings suggested that the oncogenic potential of
Ad9 E4-ORF1 depends not only on the PBM, but also on a
second protein element, which until now remained poorly
characterized. In the present study, we defined this second
crucial element, termed domain 2, through the identification of
seven point mutations that affect neither the sequence (Fig. 1)
nor the function (Fig. 4A and 5B and C) of the PBM yet
eliminate the ability of Ad9 E4-ORF1 to activate PI3K (Fig. 3)
and to transform cells (Fig. 2). As five of these mutations alter
highly conserved amino acid residues (Fig. 1), we postulate
that domain 2, like the PBM, represents a crucial protein
element common to all human Ad E4-ORF1 proteins.
We also showed that domain 2 residues collectively consti-
tute a single protein interaction element that mediates binding
to the unidentified cellular phosphoprotein pp70 (Fig. 4).
Other data indicated that domain 2 and the PBM represent
two independent protein-interaction elements in the E4-ORF1
protein (Fig. 4) and that the functional defects of domain 2
mutants do not indirectly stem from gross protein misfolding
or an inability to form functional trimers and monomers in
cells (Fig. 5). More importantly, we exposed an intimate link
between domain 2-mediated binding to pp70 and both PI3K
activation and cellular transformation induced by E4-ORF1
(Fig. 2 to 4). Thus, identification of pp70 in future studies
should aid in the delineation of molecular mechanisms that
underlie these key Ad9 E4-ORF1 activities.
The facts that domain 2 residues distribute to three widely
separated regions of the linear Ad9 E4-ORF1 polypeptide
(Fig. 1) and that E4-ORF1 trimers, but not monomers, possess
domain 2 activity (Fig. 6C) hint that E4-ORF1 trimerization
brings domain 2 residues together to form a functional protein
interaction element. Consistent with this idea, molecular mod-
eling of E4-ORF1 to the crystal structure of related trimeric
human dUTPase predicted that six out of seven domain 2
residues cluster together at each of the three subunit interfaces
in an E4-ORF1 trimer (Fig. 7). The single outlier was domain
2 residue F97, hinting that the domain 2 protein-binding sur-
face may extend beyond subunit interfaces. Results from this
analysis additionally supported a model in which an ancestral
dUTPase gene evolved into the adenovirus E4-ORF1 gene by
events that transformed the dUTPase catalytic cleft or carbox-
yl-terminal P-loop motif into E4-ORF1 domain 2 or the PBM,
respectively. This model implies that, analogous to the three
catalytic clefts and P-loop motifs present in a dUTPase trimer,
three domain 2 and PBM elements similarly exist in an E4-
ORF1 trimer. As multiple PBM elements of an E4-ORF1
trimer permit cooperative binding to the PDZ1 2 domain
tandem of Dlg1 (Chung et al., unpublished), multiple domain
2 elements may similarly allow synergistic interactions with
pp70.
Exciting new findings have revealed that domain 2 or the
PBM is independently capable of mediating E4-ORF1 local-
ization to membrane vesicles (Fig. 6A and B), which interest-
ingly represent key regulators of both protein trafficking and
signal transduction in cells (48, 53). Previous results indicated
that E4-ORF1-induced PI3K/PKB activation depends on the
PBM, due at least in part to its capacity to mediate binding to
Dlg1 (12). In the current study, we found that E4-ORF1-
induced PI3K/PKB activation additionally requires a func-
tional domain 2 (Fig. 3). Given the requirement for E4-ORF1
trimerization for both Dlg1 binding and domain 2 activity (Fig.
6C), it is tempting to speculate that an E4-ORF1 trimer as-
sembles both Dlg1 and pp70 into a single ternary complex,
which traffics on cytoplasmic membrane vesicles to the plasma
membrane and, at this site, promotes Ras-dependent PI3K
activation.
As disregulated vesicle trafficking in cells can promote un-
controlled cellular proliferation, as well as the development of
cancer, our discovery that E4-ORF1 associates with membrane
vesicles warrants further consideration. For instance, loss of
either the Tsg101 gene encoding a component of the ESCRT-I
FIG. 7. Predicted clustering of domain 2 residues at subunit interfaces of the E4-ORF1 trimer. Surface representations of the E4-ORF1 trimer
are shown from top (1), side (2), and bottom (3) viewpoints, with different monomer subunits colored white (subunit A), light gray (subunit B),
or dark gray (subunit C) and their corresponding domain 2 residues (indicated by residue number) colored blue, green, or red, respectively. In the
top and side viewpoints, a cyan-colored line circumscribes the six domain 2 residues that group together at one subunit interface. TRI and PBM
elements are colored purple and orange, respectively, with subscript A, B, and C indicating their subunit origins.
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complex or the RhoB gene encoding a small GTPase involved
in endosomal trafficking triggers cellular transformation (31)
or increased susceptibility to DMBA-induced skin carcinogen-
esis (20), respectively. Furthermore, the exocyst complex is a
direct effector for Ral GTPases, which are required for Ras-
mediated tumorigenic transformation of human cells (3), and
overexpression of the clathrin-associated oncoprotein Hip1
that regulates endocytosis is detected in multiple human epi-
thelial tumors (44). In Drosophila, disruptive mutations in
genes coding for the endocytic vesicle trafficking regulator Avl
or Rab5 or the ESCRT-II component Vps25 provoke cellular
overproliferation and neoplastic-like growths (32, 58). Also
relevant is the fact that cellular transformation induced by the
human papillomavirus type 16 E5 protein is linked to elevated
epidermal growth factor (EGF)-induced signaling caused by
decreased endosomal trafficking of activated EGF receptors to
lysosomes and increased recycling of such receptors to the
plasma membrane (9). Thus, an interesting possibility is that
E4-ORF1 similarly disregulates vesicle trafficking in cells. Con-
sistent with this idea, cellular PDZ proteins represent key
modulators of both receptor trafficking (67) and clathrin-
coated pit dynamics (43). Moreover, Dlg1 associates with
membrane vesicles, as well as the Hrs protein that regulates
endosomal trafficking, and the Drosophila Dlg1 homologue
controls vesicle trafficking necessary for plasma membrane for-
mation (6, 27). Likewise, MUPP1 accumulates in membrane
vesicles of Caco-2 cells unable to express the CAR receptor (8)
and MAGI-1 binds the endocytic receptor megalin in kidney
cells (41).
Previous findings revealed that E4-ORF1 stimulates the
PI3K/PKB pathway by a Ras-dependent mechanism that fails
to similarly activate the Ras/MAPK/ERK pathway (12, 13).
Interestingly, vesicle trafficking has been reported to differen-
tially affect membrane signaling from these two important
pathways. For example, inhibition of endocytosis enhances
PKB, but not ERK, activation by the EGF receptor (10) or
blocks ERK, but not PKB, activation by either insulin receptor
or the RET tyrosine kinase receptor (5, 45). Additionally,
overexpression of the transforming protein intersectin, which
inhibits clathrin-mediated endocytosis, promotes Ras-depen-
dent activation of PKB, but not ERK, in cells (59). Based on
these observations, together with the results presented in this
paper, we plan in future studies to investigate whether E4-
ORF1 domain 2- and PBM-interacting cellular factors function
to regulate vesicle trafficking and whether PI3K activation and
cellular transformation induced by E4-ORF1 stem from its
ability to perturb this fundamental key process in cells.
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